Pharmacy Question for the Week of April 13, 2020

Pharmacy Compliance Question of the Week


What is the status indicator change for Q5118?


According to the April Outpatient Perspective Payment System updates in Transmittal 10013: “The status indicator for HCPCS code Q5118 (Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg) will be changed retroactively from status indicator =”E2” to status indicator = “K”, Effective January 13, 2020.”

CPT© copyright 2020 American Medical Association (AMA). All rights reserved.

Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

CPT is a registered trademark of the American Medical Association.